Sinopharm’s new crown vaccine has been approved for emergency use in more than ten countries and regions

Many countries in the world are continuing to promote the new crown vaccination, and the safety, effectiveness, and accessibility of China’s vaccine have been recognized by many countries. Yang Xiaoming, chairman of Sinopharm China Biotechnology Co., Ltd. and chief scientist of the national “863” plan vaccine project, said in an exclusive interview with Xinhua News Agency reporters that building a global immune defense line through vaccination requires the concerted efforts of all countries, and Chinese companies are promoting The fair distribution of vaccines fulfills due obligations.

Yang Xiaoming said that the global population is more than 7 billion, and the susceptible population of the new crown virus is the entire population. Countries around the world need to work together in vaccination, personal protection, community management and other aspects to effectively control the epidemic.

He said that China has decided to provide 10 million doses of vaccine to the “New Coronary Pneumonia Vaccine Implementation Plan”, mainly for the urgent needs of developing countries, and fulfill its commitment to make the new crown vaccine a global public product through practical actions.

According to the data provided by Sinopharm Group, the current Sinopharm China Bio-New Crown Inactivated Vaccine has been approved for emergency use in more than ten countries and regions including Hungary, Seychelles, Pakistan, Morocco, and registered in the United Arab Emirates and Bahrain. Approved for conditional listing.

Yang Xiaoming said that at present, most of the countries that export and supply domestic vaccines produced by Sinopharm, China Biological, etc. are developing countries. These countries basically have no ability to develop or produce new crown vaccines. Compared with other countries, they need vaccines. Chinese companies are working to promote vaccine equity. Allocate due obligations.

Compared with developed countries, developing countries and underdeveloped countries have very limited purchasing capacity and vaccine storage and transportation conditions. Yang Xiaoming believes that China’s new crown vaccine has lower cost, large production, and storage and transportation conditions of 2 to 8 degrees Celsius, which are consistent with the existing vaccine storage and transportation conditions in many countries. There is no need to restructure the cold chain system and facilities, and the accessibility is higher. It can better help third world countries to prevent and control the epidemic.

In Yang Xiaoming’s view, many Chinese new crown vaccines, including inactivated vaccines, are already in the “first phalanx” of global new crown vaccine research and development. This shows that the overall research and development capabilities, technological equipment and supervision levels of China’s vaccine industry have been over 40 years of reform and opening up. Significant improvement, achieving a breakthrough from “following” to “paralleling”, and even “leading” of individual varieties.

“Now our R&D and production process is completely different from the inactivated vaccine process decades ago. It can be said to be a completely reborn change-process improvement and technological breakthrough.” Yang Xiaoming said, Sinopharm China Biotech The new crown inactivated vaccine adopts advanced cell culture technology, purification technology, etc., with high production efficiency and quality control indicators that have reached the international advanced level.

Chinese vaccine companies are working overtime to expand production capacity to ensure that the new crown vaccine is delivered to the urgently needed areas as soon as possible. Yang Xiaoming introduced that the production capacity of Sinopharm’s China Bio-New Crown Vaccine is expected to reach over 1 billion doses this year. vaccine”.

(Participating reporters: Wang Pei and Zheng Kaijun, the original title is “Interview: Safe and Effective Chinese Vaccine Helping Global Epidemic Prevention and Control-Interview with Yang Xiaoming, Chairman of Sinopharm Group China Biotech”)